Worldwide Adoption of Ekso Bionics® EksoGT™ Exoskeleton Allows Stroke and Spinal Cord Injury Patients to Take 100 Million Steps to Date
More than 240 leading rehabilitation centers in over 30 countries helped their patients walk 50,000 miles in the EksoGT exoskeleton during rehab sessions— the distance of walking around the world twice
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industry use, today announced that the worldwide adoption of the EksoGT™ exoskeleton has allowed stroke and spinal cord injury patients to take 100 million steps to date (click to tweet). More than 240 leading rehabilitation centers in over 30 countries helped their patients walk 50,000 miles in the EksoGT exoskeleton— the distance of walking around the world twice.
Centers utilizing the EksoGT are advancing both in-patient and outpatient rehabilitation, and collectively changing the standard of care to promote better patient outcomes.
As the exoskeleton most widely used in rehabilitation, the EksoGT:
is designed to help patients get back on their feet by supporting re-learning of correct step patterns, weight shifting, and potentially mitigating compensatory behaviors, enabling patients to mobilize earlier and restore independence
is the only exoskeleton with SmartAssistTM software which provide adaptive amounts of power to either side of a patients body, especially beneficial for stroke patients
provides the ability to mobilize patients earlier, more frequently, and with a greater number of high intensity steps
For patients who never thought they would walk or even stand again, the EksoGT also offers hope.
"Ekso Bionics set out to change the standard of care in rehabilitation with unparalleled exoskeleton technology," said Jack Peurach, CEO and President of Ekso Bionics. "And, thanks to our Centers of Excellence and other leading rehabilitation centers, together we were able to achieve the 100 million steps milestone. These centers are thought leaders and understand how to use our technology as a tool to improving the lives of their patients. We are excited to continue to grow the presence of the EksoGT worldwide so we can continue improving the lives of all of those who suffer a stroke or spinal cord injury."
Each year, more than 15 million people experience a stroke and 500,000 individuals develop a spinal cord injury worldwide. This cutting-edge exoskeleton technology augments strength to help patients get back on their feet sooner and walk, while gaining confidence and freedom. Clinical evidence shows that including EksoGT gait training during rehabilitation can improve patient gait speed and walking distance outside of the device at discharge compared to admission and may improve independence in functional mobility during inpatient stroke rehabilitation.
"Our Barrow neuro robotics program works to combine customized robotics with trained functional therapy to maximize outcomes for neurological patients. The EksoGT is a significant piece in our neuro robotics program and allows our team to further customize rehabilitation care," said Chris St. Clair, Senior Director of Rehabilitation Services at Dignity Health in Arizona.
Learn more about innovative centers that are leading the way in exoskeleton rehabilitation by visiting Ekso Bionics Centers of Excellence.
EksoGT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. In Europe, the CE-Mark cleared EksoGTTM allows us to work with patients impacted by all neurological conditions and lower limb weakness. The EksoGT™ with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of a patients body, challenging the patient as they progress through their continuum of care. The suits patented technology provides the ability to mobilize patients earlier, more frequently, and with a greater number of high intensity steps. To date, this device has helped patients take 100 million steps in over 240 rehabilitation institutions around the world.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.